Jennifer B. Vidler

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.

Clinical heterogeneity and outcome of acquired PRCA: a multicenter European study.

Journal: Blood advances

Published: December 24, 2025

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Journal: Blood advances

Published: December 24, 2025

Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience.

Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience.

Journal: American journal of hematology

Published: July 17, 2025

Proliferating CLL cells express high levels of CXCR4 and CD5.

Proliferating CLL cells express high levels of CXCR4 and CD5.

Journal: HemaSphere

Published: September 03, 2024

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Journal: Blood advances

Published: June 18, 2024

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Journal: Blood neoplasia

Published: April 15, 2024

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Journal: Blood

Published: July 07, 2023

Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.

Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.

Journal: Cancer research communications

Published: February 24, 2023

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Journal: British journal of haematology

Published: December 21, 2022

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes.

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes.

Journal: Haematologica

Published: November 15, 2021

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.

Journal: Cancer cell

Published: October 22, 2021

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.

Journal: The Lancet. Oncology

Published: March 11, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026